346 fresh cases take infection tally to 11000 mark
Eight more patients died of COVID-19 in Jammu and Kashmir during the past 24 hours taking the death toll to 195, including 177 from the valley.
A 60-year-old man from Nadihal, Baramulla admitted to SKIMS Srinagar on July 05 died today after battling for life on a ventilator for four days with oxygen support.
Medical Superintendent SKIMS, Dr Farooq Jan said the deceased was suffering from hypertension, diabetes, chronic kidney disease, and end-stage renal disease.
A 60-year-old man from Tangmarg area of Baramulla admitted to the Institute’s medical emergency on July 13 as a suspected case of coronavirus succumbed today.
“His sample was taken on the same day. The patient was sick and died today,” Jan said adding the deceased was on oxygen support for one day.
A 35-year-old paramilitary CRPF man posted at 66 Battalion in Baramulla, who died on Monday, tested positive for coronavirus today. The deceased, a resident of Nowshera Rajouri, was suffering from fever and pneumonia.
A 65-year-old coronavirus patient from Shopian died at SKIMS Medical College and Hospital Bemina.
“He was admitted on July 10. He already had coronary bypass surgery and was also suffering from pneumonia,” hospital’s Medical Superintendent, Dr Shifa Deva said.
Two women both 60 from Anantnag and Kulgam died at GMC Anantnag on July 10. They tested positive for COVID-19 late Monday night.
A 47-year-old man from Jammu died at GMC Jammu. The man was a government employee and was admitted to the hospital on July 12 later put on a ventilator.
As per the doctors, he was suffering from severe fever, cough bilateral community acquired pneumonia, acute respiratory distress syndrome and hypertension.
The deceased was on oxygen support after his admission.
Eighth death has been reported from south Kashmir’s Kulgam district.
With eight fresh casualties, the death toll due to the novel coronavirus has soared to 195 in J&K including 177 from Kashmir and 18 from Jammu.
The government said Srinagar has witnessed 46 deaths, Baramulla 38, Kulgam 22, Shopian 17, Anantnag 15, Budgam 14, Kupwara and Jammu 11 each, Pulwama seven, Ganderbal four, Bandipora three, Doda two, Udhampur, Kathua, Samba, Poonch, and Rajouri one each.
Not only deaths, coronavirus cases continue to go up in J&K Tuesday witnessed 346 new cases including 29o from Kashmir and 56 from Jammu taking the infection tally to 11173.
Tuesday’s cases include 127 from Srinagar, Anantnag 58, Pulwama 39, Bandipora 16, Budgam, Doda 14 each, Baramulla, Shopian, Jammu 11 each, Rajouri 10, Kulgam seven, Kishtwar five, Ganderabl four, Kupwara, Reasi three each and Ramban, Samba, Poonch one each.
Of these cases, 117 returned positive at Viral Diagnostic and Research Lab (VDRL) of SKIMS Srinagar, which tested 2424 samples in the past 24 hours.
Medical Superintendent SKIMS, Dr Farooq Jan said they include 34 from Srinagar, Anantnag 18, Pulwama 16, Budgam 10, Baramulla nine, eight paramilitary CRPF and SSB men, Kulgam eight, Bandipora seven, Kupwara, Ganderbal two each, Shopian Kargil and Banihal one each.
Similarly, the COVID-19 testing lab of SKIMS Medical College and Hospital, Bemina Tuesday tested 540 samples of which 48 returned positive, all from Srinagar.
The government said of the 4,66,333 test results available, 4,55,160 returned negative and 11173 positive which include 4755 active positive cases while 6223 have recovered and been discharged including 128 persons discharged during the past 24 hours.
It said, so far, 3,17,904 persons had been put under observation including 38,211 in home quarantine, 4755 in hospital isolation and 24 in hospital quarantine while 45,537 people are under home surveillance and 2,29,182 persons have completed their surveillance period.
In Kashmir, Srinagar tops list with 1933 cases, followed by Baramulla with 1337, Kulgam 1028, Shopian 929, Anantnag 860, Kupwara 805, Pulwama 701, Budgam 586, Bandipora 401 and Ganderbal 205.
In Jammu division, Jammu has 524 cases followed by Udhampur with 303, Kathua 326, Ramban 271, Samba 269, Rajouri 285, Poonch 147, Doda 148, Reasi 60 and Kishtwar 55.
There are two Indian vaccine candidates that have undergone successful toxicity studies in rats, mice and rabbits and this data was submitted to the DCGI, following which both got clearance to start an early phase human trials earlier this month, Bhargava said at a press briefing.
"Two indigenous Indian candidate vaccines have got clearance to start early phase human trials this month.
"They have got their sites ready and are doing the clinical study on approximately 1,000 human volunteers each at different sites. They are trying to do early clinical testing for these two indigenous vaccine candidates," Bhargava said.
"... it is a moral duty to develop them as fast as possible because more than half a million people have succumbed to the disease across the world. So, fast-tracking these vaccines becomes very important," he said.
A recent letter by Bhargava envisaging the launch of a COVID-19 vaccine by August 15 had created quite a flutter with many experts stating such a timeline may not be realistic.
Bhargava stated that India is considered as the "pharmacy of the world", saying 60 per cent of the drugs used in the US are of Indian origin.
"The important fact that is not known is that 60 per cent of the vaccines supplied in the world whether it be Africa, Europe or Southeast Asia or anywhere are of Indian origin," he said.
India is perceived and is an important player in the supply of vaccines for the world, Bhargava noted.
"Any vaccine candidate that is produced or developed in any part of the world will ultimately have to be scaled up by India or by China because these two are major producers of vaccines in the world and that every developed nation or everyone trying to develop a vaccine are aware of it and therefore they are in communication with India for the vaccine distribution ultimately if is developed," he said.
Bhargava said that recently Russia had fast-tracked a vaccine, which has been successful in its early phases, and they have also accelerated its development and the whole world has applauded it.
"The US again, as you read today has fast-tracked two of its vaccine candidates and the UK is also looking at how it can fast-track the Oxford vaccine candidate, for human use.
"From India's perspective, we have two vaccine candidates. We are trying all out efforts to fast-rack it and it is the moral duty that there should not be a delay not even by a day for regulatory clearances for these vaccines so that we can break the transmission of the virus as soon as possible,” Bhargava said.
He emphasised that still 60 per cent of the other vaccines whether it be polio, measles-rubella they are all manufactured in India and are given to the international agencies to supply to the world so this becomes an important aspect for India to fast-track its vaccine development and work together to develop these vaccines for the entire world.